Coeptis Therapeutics Inc COEP 深 沪
等待开盘 11-04 09:30:00 美东时间
15.43
+0.210
+1.38%
华盛通- 最 高15.48
- 今 开15.48
- 成交量 2.65万股
- 最 低 14.9521
- 昨 收 15.22
- 总市值 5421.79万
- 52周最高 19.19
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 2.622
- 委 比 33.33%
- 总股本 351.38万
- 历史最高 428.40
- 量 比 1.22
- 振 幅 3.47%
- 历史最低 2.622
- 每 手 1
- 风险率 3.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating
Coeptis Therapeutics (NASDAQ: COEP) is pioneering a dual-track model to sustain innovation while reducing reliance on dilutive funding. In Q2 2025, the company generated $200,681 in revenue while advancing its GEAR Cell Therapy Platform for cancer treatment. Its NexGenAI platform provides complementary revenue streams, allowing the company to maintain control over research and equity. The global cell therapy market's growth presents opportunities...
09-23 12:00
Coeptis Therapeutics Q2 EPS $(1.17) Up From $(1.60) YoY, Sales $200.681K
Coeptis Therapeutics (NASDAQ:COEP) reported quarterly losses of $(1.17) per share. This is a 26.88 percent increase over losses of $(1.60) per share from the same period last year. The company reported $200.681 thousand
08-15 05:48
Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd
Coeptis Therapeutics Holdings, Inc. announced the extinguishment of its convertible note with YA II PN, Ltd (Yorkville), eliminating its debt obligations to the company. CEO David Mehalick stated this strengthens the Company’s capital structure, aiding in strategic expansion into the cryptocurrency space. Coeptis focuses on developing innovative cell therapies, with assets including allogeneic cellular immunotherapy and unmodified natural killer ...
07-22 12:36
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: COEP, RHE, PPBI, and PORT
NEW YORK, July 3, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...
07-04 05:31
Coeptis Therapeutics Files Form S-4 With SEC For Proposed Merger With Z Squared
Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, is pleased to announce the filing of a registration statement on Form S-4 with the
06-26 20:37
Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared
Coeptis Therapeutics Holdings, Inc. announced the filing of a Form S-4 registration statement with the SEC regarding its proposed merger with Z Squared Inc. The transaction involves combining Coeptis, a biopharmaceutical and technology company focused on cell therapies, with Z Squared, a digital asset mining company. The Form S-4 includes a preliminary proxy statement/prospectus, which will be finalized once the registration statement is effectiv...
06-26 12:34
SNAP Biosciences & Monarch Therapeutics Partner To Advance Snap-Car NK Cell Therapy
SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics Holdings Inc. (NASDAQ:COEP) and Monarch Therapeutics Inc., a biotechnology company pioneering next-generation immunotherapies, today announced a
05-28 20:29
Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
SNAP Biosciences and Monarch Therapeutics have inked a licensing agreement to integrate Monarch's small molecule adaptor technology with SNAP's Snap-CAR NK cell therapy platform, enhancing its precision, flexibility, and scalability for oncology applications. This collaboration aims to address tumor heterogeneity and improve outcomes for patients with hard-to-treat cancers. Monarch will receive upfront payments and royalties under the agreement.
05-28 12:28
NUBURU Advances $100M Capital Raise And Strategic Acquisition Of Defense & Security Hub Pending Italian 'Golden Power' Approval, Aiming To Drive Over $50M In 2025 Revenue While Relaunching Blue Laser Business
NUBURU Poised to Finalize Strategic Acquisition and Prepare the Adoption of Advanced Technology, Artificial Intelligence & Robotics Initiatives as It Awaits Italian Government ‘Golden Power' ApprovalNUBURU, Inc.
05-12 20:25
Dogecoin Up 9% In One Week: Is A Breakout Coming?
Dogecoin (CRYPTO: DOGE) is up 9% over the past week, with key technical signals suggesting a possible breakout.
04-29 19:55
